Navigation Links
SIRO Clinpharm Announces Appointment of Gopakumar Menon as Chief Executive Officer to Lead the Global Clinical Research Organization
Date:3/7/2012

MUMBAI, India, March 7, 2012 /PRNewswire/ --

SIRO Clinpharm, a leading full service Clinical Research Organization announced the appointment of Gopakumar Menon as Chief Executive Officer. SIRO has developed a long term plan to align with the changing dynamics of the biopharma industry, and his primary charter is to transform SIRO into a global leader in the CRO and FSP space. He will be responsible for continuing to build and enhance the biopharma service catalog for SIRO's global delivery model, across the Americas, Europe and Asia.

"It is a pleasure to have Gopakumar on board. Gopakumar brings with him rich experience in driving business growth, and delivering tremendous value for leading companies, including Fortune 1000 companies," said Dr. Gautam Daftary, Chairman of SIRO Clinpharm. "Gopakumar has an excellent track record in cultivating partnership based relationships with Fortune 500 pharmaceutical client base, envisioning cutting-edge business and technical solutions for clients across U.S., Europe, Japan, India, China and Singapore. His experience and knowledge will help SIRO to enhance its services, and build a strong presence in new markets where the company plans to expand its frontiers."

"The biopharma industry is undergoing significant transformations. Clients are actively seeking quality service providers from the emerging markets, who can understand their specific challenges, and partner to build and deliver innovative solutions in a global delivery model," said Gopakumar. "My first priority will be to leverage decades of experience, tremendous value, and geographic reach of SIRO to make it the partner of choice for business critical services of global biopharma leaders. I look forward to working with Gautam and SIRO's board of directors."

Gopakumar has been with the pharmaceutical industry for the more than 12 years, where he worked in various capacities, from discovery to sales and marketing.

Prior to joining SIRO Clinpharm, Gopakumar was with Boston based Sciformix Inc. Gopakumar has had significant experience working with Fortune 500 companies like Cognizant and Satyam, in their Life Sciences divisions, as well as with venture funded start-up organizations.

About SIRO:

SIRO Clinpharm, winner of Frost & Sullivan Indian Clinical Research Organization of the year 2011 award, is a drug development solutions provider to the global healthcare industry. Our subject expertise gives us an edge in data management, medical writing, biostatistics & clinical trial management. Having a successful track record of 16 years, SIRO works with most top global biopharma & medical device companies. Our therapeutic experience includes but is not limited to oncology, diabetes, cardiology, infectious diseases & respiratory system. We offer flexible business models across service verticals based on client needs.

The company has offices in India, Malaysia, USA, and Israel and in Europe at Germany, Romania, Estonia, Greece, Czech Republic and Spain.

For more information please visit our website- http://www.siroclinpharm.com

Media contact:

Ruchi Sanganeria
Corporate Marketing
Tel: +91-22-2584-8000
ruchi.sanganeria@siroclinpharm.com


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
2. SIRO Clinpharm and CambReg Ltd Strategic Alliance to Offer Regulatory Services in Europe
3. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
4. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
5. SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS
6. SIRO Clinpharms Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM)
7. SIRO Clinpharm Expands Presence in Asia
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... COLOGNE, Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to ... http://photos.prnewswire.com/prnh/20160503/362920    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... ACME Markets, Delaware County ... County Councilman Dave White announced today the ... ACME pharmacies across Delaware County . ... naloxone has saved 26,463 lives nationwide over the past 20 years. ... were authorized to administer naloxone to overdose victims, 244 ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every ... the most heartfelt wishes of these children. The wishes provide hope and ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization ...
(Date:5/5/2016)... ... ... A recent survey by the Midwest Business Group on Health ... use the free preventive care benefits available to them as part of the Affordable ... public and private employers, MBGH found that only 10% of large employers are aware ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade students ... , Director of Allergy and Asthma Clinical Research in the Division of Pulmonary, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... presented a talk highlighting the organization’s successful Care Transitions program at ... The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions ...
Breaking Medicine News(10 mins):